drugset / Trial / NCT06710223
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
Phase 1
Recruiting
20 enrolled
University of California, San Diego
Boston Scientific Corporation · collabTriSalus Life Sciences, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma. After this procedure, participants will be treated with tremelimumab and durvalumab every 4 weeks (STRIDE regimen).
Timeline
- Start
- 2025-01-03
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Nelitolimod | Oligonucleotide (other) | — | Other |
| Subject | Tremelimumab | Monoclonal antibody | 300 mg | Intravenous |